標(biāo)題: Titlebook: Regulation of Cancer Immune Checkpoints; Molecular and Cellul Jie Xu Book 2020 The Editor(s) (if applicable) and The Author(s), under exclu [打印本頁(yè)] 作者: Guffaw 時(shí)間: 2025-3-21 19:38
書(shū)目名稱Regulation of Cancer Immune Checkpoints影響因子(影響力)
書(shū)目名稱Regulation of Cancer Immune Checkpoints影響因子(影響力)學(xué)科排名
書(shū)目名稱Regulation of Cancer Immune Checkpoints網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Regulation of Cancer Immune Checkpoints網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Regulation of Cancer Immune Checkpoints被引頻次
書(shū)目名稱Regulation of Cancer Immune Checkpoints被引頻次學(xué)科排名
書(shū)目名稱Regulation of Cancer Immune Checkpoints年度引用
書(shū)目名稱Regulation of Cancer Immune Checkpoints年度引用學(xué)科排名
書(shū)目名稱Regulation of Cancer Immune Checkpoints讀者反饋
書(shū)目名稱Regulation of Cancer Immune Checkpoints讀者反饋學(xué)科排名
作者: 釘牢 時(shí)間: 2025-3-21 23:32 作者: Muscularis 時(shí)間: 2025-3-22 03:01 作者: 一再遛 時(shí)間: 2025-3-22 07:44
Chushu Li,Bingqing Xia,Sheng Wang,Jie Xuprovision in host countries. It is of interest to all those who provide health services, create policy, and initiate legislation for these populations..978-1-4419-3556-4978-0-387-22693-4Series ISSN 1571-5507 Series E-ISSN 2197-7984 作者: escalate 時(shí)間: 2025-3-22 11:59 作者: Disk199 時(shí)間: 2025-3-22 14:41 作者: BLANC 時(shí)間: 2025-3-22 18:28
Yiting Wang,Ping Wang,Jie Xuprovision in host countries. It is of interest to all those who provide health services, create policy, and initiate legislation for these populations..978-1-4419-3556-4978-0-387-22693-4Series ISSN 1571-5507 Series E-ISSN 2197-7984 作者: 小母馬 時(shí)間: 2025-3-22 21:39 作者: 彩色 時(shí)間: 2025-3-23 03:07
Haojie Lu,Caiyun Fangprovision in host countries. It is of interest to all those who provide health services, create policy, and initiate legislation for these populations..978-1-4419-3556-4978-0-387-22693-4Series ISSN 1571-5507 Series E-ISSN 2197-7984 作者: tinnitus 時(shí)間: 2025-3-23 06:32 作者: 要素 時(shí)間: 2025-3-23 10:24 作者: stratum-corneum 時(shí)間: 2025-3-23 14:32 作者: antiquated 時(shí)間: 2025-3-23 19:41 作者: Cerebrovascular 時(shí)間: 2025-3-23 22:21 作者: 牙齒 時(shí)間: 2025-3-24 02:54 作者: Handedness 時(shí)間: 2025-3-24 08:44
Luoyan Ai,Antao Xu,Jie Xus in experiments 5 and 6 with distinct objects flexibility. Experiments 7 and 8 evaluate the performance of the suggested DRAFC strategy for peg-in-hole assembly processes of rigid and flexible objects, respectively. The performance of the proposed position hole identification scheme is studied in e作者: 細(xì)胞 時(shí)間: 2025-3-24 13:52
Xuan Kongen largely ignored at the levels of both research and policy. Thus far, national policy has merely consisted of ad hoc ministerial decrees tending to respond to emergencies in the chain of events related to displacement (Assal 2006a). The few policies that have been adopted centre around meeting the作者: lattice 時(shí)間: 2025-3-24 17:43
Hubing Shi,Jiang Lan,Jiqiao Yanglasted for an unprecedented length of time — three months — from the end of September until 30 December (see Grabska, this volume, and Gomez et al. 2005a, 2005b).. The difference with these protests that are happening in the ‘global South’ is that refugees are demonstrating against the UNHCR, not th作者: Extricate 時(shí)間: 2025-3-24 21:56 作者: 大廳 時(shí)間: 2025-3-25 03:03
Molecular and Cellular Functions of CTLA-4,intrinsic CTLA-4 signaling has been implicated in T-cell motility and the regulation of CTLA-4 its subcellular localization amongst others. CTLA-4 is well recognized as a key immune checkpoint and has gained significant momentum as a therapeutic target in the field of autoimmunity and cancer. In thi作者: tenosynovitis 時(shí)間: 2025-3-25 05:56
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond, of PD-L1. This provides the scientific rationale for clinical application of immune checkpoint inhibitors in oncology. The aberrantly high expression of PD-L1 in tumor microenvironment (TME) can be attributable to the “primary” activation of multiple oncogenic signaling and the “secondary” inductio作者: 擴(kuò)音器 時(shí)間: 2025-3-25 11:15
Discovery of New Immune Checkpoints: Family Grows Up,ted toxicities, some are life-threatened and with higher incidence in I-O combination regiment. Moreover, clinicians observed some cases switching to progression after achieving partial or complete response, indicating treatment failure or drug resistance. So people begin looking for the next genera作者: Neonatal 時(shí)間: 2025-3-25 13:47 作者: 乳汁 時(shí)間: 2025-3-25 18:00
Molecular Events Behind Adverse Effects,gut immune tolerance toward dietary antigens and commensals, and anti-inflammatory function in intestines are maintained mainly by Treg cells. Furthermore, tissue residency of functional T cells depends on the homing/trafficking to the locations of inflammation. Here, we review the role of microbiot作者: Rinne-Test 時(shí)間: 2025-3-25 22:35 作者: strdulate 時(shí)間: 2025-3-26 03:45 作者: 饑荒 時(shí)間: 2025-3-26 06:07
Folded or Degraded in Endoplasmic Reticulum,onged ER stress ultimately results in cell death. This chapter reviews the process that proteins undergo in the ER, and the glycosylation, folding and degradation of immune checkpoint proteins as well as the associated potential immunotherapies to date.作者: 消極詞匯 時(shí)間: 2025-3-26 10:19
Regulation of Cancer Immune Checkpoint: Mono- and Poly-Ubiquitination: Tags for Fate,e selectively recruits specific protein substrates through specific protein-protein interactions to determine the specificity of the overall ubiquitin modification reaction. Immune-checkpoint inhibitory pathway is an important mechanism for tumor cells to evade immune killing, which can inhibit T ce作者: CANON 時(shí)間: 2025-3-26 13:08
Phosphorylation: A Fast Switch For Checkpoint Signaling,d CTLA-4, because investigations concerning them are particularly abundant and variant. Their distinct regulation is supplementarily discussed in their respective section. As for checkpoints that are so far not well explored, their related phosphorylation modulations are listed separately in the lat作者: bile648 時(shí)間: 2025-3-26 19:13
Checkpoints Under Traffic Control: From and to Organelles, include metformin, chemokine-like factor-like MARVEL transmembrane domain-containing family member (CMTM), Huntingtin-interacting protein 1-related (HIP1R), exosomes, ALIX, polyI:C, and various post-translational modifications. Here, we focus on the checkpoints under traffic control, counting PD-L1作者: 講個(gè)故事逗他 時(shí)間: 2025-3-27 01:00 作者: 外表讀作 時(shí)間: 2025-3-27 02:12
Book 2020athways are still in their infancy. ..To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune che作者: 禁止 時(shí)間: 2025-3-27 07:22 作者: SOBER 時(shí)間: 2025-3-27 09:40
Molecular and Cellular Functions of CTLA-4,T-cells. Its ligands, CD80 and CD86, are typically found on the surface of antigen-presenting cells and can either bind CD28 or CTLA-4, resulting in a costimulatory or a co-inhibitory response, respectively. Because of its dampening effect, CTLA-4 is a crucial regulator of T-cell homeostasis and sel作者: 鋼盔 時(shí)間: 2025-3-27 14:19
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond,eceptors expressed on T cells upon T cell activation. After engagement with its ligands, mainly PD-L1, PD-1 is activated and recruits the phosphatase SHP-2 in proximity to T cell receptor (TCR) and CD28 signaling. This event results in dephosphorylation and attenuation of key molecules in TCR and CD作者: indignant 時(shí)間: 2025-3-27 18:25
Discovery of New Immune Checkpoints: Family Grows Up,ll 2019 Q1, there are nine ICIs landing the oncology market: Ipilimumab (anti-CTLA-4, Bristol-Myers Squibb), Nivolumab (anti-PD-1, Bristol-Myers Squibb), Pembrolizumab (anti-PD-1, Merck), Atezolizumab (anti-PD-L1, Roche/Genentech), Durvalumab (anti-PD-L1, Astra Zeneca), Tremelimumab (anti-CTLA-4, As作者: 鬧劇 時(shí)間: 2025-3-28 00:33 作者: 西瓜 時(shí)間: 2025-3-28 04:10 作者: stratum-corneum 時(shí)間: 2025-3-28 06:41
Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoie. However, response rate of this promising therapy is low, thus requiring biomarkers for precise medication to reduce the ineffective treatment. With multiple retrospective clinical studies, more and more candidate prognostic factors have been identified with possible mechanic explanation, includin作者: 數(shù)量 時(shí)間: 2025-3-28 10:49 作者: 溫和女孩 時(shí)間: 2025-3-28 17:25 作者: 善于 時(shí)間: 2025-3-28 18:57 作者: Missile 時(shí)間: 2025-3-29 02:10 作者: 單色 時(shí)間: 2025-3-29 06:44
Folded or Degraded in Endoplasmic Reticulum,lum (ER) to acquire their native functional structures before they function at their destinations. There are various ER-resident chaperones and enzymes synergistically regulate and catalyze the glycosylation, folding and transporting of proteins. The whole processing is under the surveillance of ER 作者: 一加就噴出 時(shí)間: 2025-3-29 08:55 作者: 磨碎 時(shí)間: 2025-3-29 13:14
Lysosome as the Black Hole for Checkpoint Molecules,ocesses. In normal physiological conditions, lysosomes can sense the nutritional state and be responsible for recycling raw materials to provide nutrients, affecting cell signaling pathways and regulating cell proliferation. Lysosomes are related to many diseases and associated with metastasis and d作者: Malcontent 時(shí)間: 2025-3-29 17:40 作者: 木質(zhì) 時(shí)間: 2025-3-29 20:10
Palmitoylation as a Signal for Delivery,e lipid modification. Our recent work demonstrated that palmitoylation reduces the lysosomal degradation of PD-L1 trafficking and may present a new therapeutic target. To facilitate future investigations on palmitoylation and immune checkpoints, here we summarize the molecular roles of palmitoylatio作者: 成績(jī)上升 時(shí)間: 2025-3-30 03:44 作者: set598 時(shí)間: 2025-3-30 06:14
Checkpoints Under Traffic Control: From and to Organelles,heckpoints include programmed cell death protein 1 (PD1), programmed death-ligand 1 or 2 (PD-L1 or PD-L2), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and so on. While the immune checkpoint molecules have gained soaring attention in recent years, the trafficking of them has been rarely stu作者: ADOPT 時(shí)間: 2025-3-30 09:12 作者: floaters 時(shí)間: 2025-3-30 14:36
Introduction,ave gained insights into the molecular control of immune checkpoint receptors and ligands, which extended our knowledge on the immune system and provided alternative strategies for developing checkpoint inhibitors.作者: habitat 時(shí)間: 2025-3-30 18:09
Regulations on Messenger RNA: Wires and Nodes,n this chapter, we reviewed the RNA processing mechanisms directly regulating immune checkpoint genes. We also cover RNA-based therapeutic strategies aiming at restoring immunity by targeting immune checkpoint genes.作者: dagger 時(shí)間: 2025-3-31 00:30 作者: Panther 時(shí)間: 2025-3-31 04:35 作者: Dendritic-Cells 時(shí)間: 2025-3-31 07:51
Genetic Alterations and Checkpoint Expression: Mechanisms and Models for Drug Discovery,ve marked a great achievement in the history of antitumor therapy. Nevertheless, this is not the end of the story. As the relationship between genomic alteration and checkpoint expression is being delineated though the advances of preclinical animal models and emerging technologies, novel checkpoint targets are on the way to be discovered.作者: Antigen 時(shí)間: 2025-3-31 12:47
Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoi of all the possible candidate biomarkers are still challenging to predict the treatment outcomes. In this chapter, we will summarize and introduce the prognostic factors and biomarkers for checkpoint inhibitor-based immunotherapy.作者: forbid 時(shí)間: 2025-3-31 14:19
Lysosome as the Black Hole for Checkpoint Molecules,mmune checkpoint proteins. Once activated, the compounds contained in secretory lysosomes are released to the surface of cell membrane rapidly. Inhibitions of lysosomes can overcome the chemoresistance of some tumors and enhance the efficacy of immunotherapy.作者: Dna262 時(shí)間: 2025-3-31 18:33 作者: COST 時(shí)間: 2025-3-31 23:08
Book 2020largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA作者: 寬度 時(shí)間: 2025-4-1 03:52 作者: NOVA 時(shí)間: 2025-4-1 09:19
Jie Liu,Jie Xuntrol. Novel ideas and innovations related to this area are presented and reported in detail, and examples of applications in medical technology are given..The book begins by introducing force sensing, and modelling of contacting objects. In then moves steadily through a variety of topics, including作者: 細(xì)節(jié) 時(shí)間: 2025-4-1 11:38
Samya Van Coillie,Bartosz Wiernicki,Jie Xu schemes. Experiments 1–6 are dedicated for the performance evaluation of the proposed EM-GMM CS recognition scheme for multiple rigid and flexible objects with different shapes and geometry. More specifically, experiment 1 addresses employing the proposed EM-GMM CS recognition scheme for the rigid 作者: 半球 時(shí)間: 2025-4-1 16:28 作者: 饑荒 時(shí)間: 2025-4-1 20:30 作者: VAN 時(shí)間: 2025-4-2 02:43
Hubing Shi,Jiang Lan,Jiqiao Yanghapters by Grabska, Mehta in this volume). It is not unusual to read about refugee protests, hunger strikes, or even suicides in Europe, Australia or North American countries when they have been detained facing prolonged incarceration or immediate deportation,. but during 2005 there were unparallele
